Evidence map›Paper›PMID 38627676›Full record

ArticleBMC genomics2024

Identification of skewed X chromosome inactivation using exome and transcriptome sequencing in patients with suspected rare genetic disease.

Numrah Fadra, Laura E Schultz-Rogers, Pritha Chanana, Margot A Cousin, Erica L Macke, Alejandro Ferrer, Filippo Pinto E Vairo, Rory J Olson, Gavin R Oliver, Lindsay A Mulvihill and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Numrah FadraQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Laura E Schultz-RogersQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Pritha ChananaQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Margot A CousinQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Erica L MackeQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Alejandro FerrerQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Filippo Pinto E VairoQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Rory J OlsonQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Gavin R OliverQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Lindsay A MulvihillQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Garrett JenkinsonQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Eric W KleeQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA. Klee.Eric@mayo.edu.
Mayo Clinic in Florida · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundX-chromosome inactivation (XCI) is an epigenetic process that occurs during early development in mammalian females by randomly silencing one of two copies of the X chromosome in each cell. The preferential inactivation of either the maternal or paternal copy of the X chromosome in a majority of cells results in a skewed or non-random pattern of X inactivation and is observed in over 25% of adult females. Identifying skewed X inactivation is of clinical significance in patients with suspected rare genetic diseases due to the possibility of biased expression of disease-causing genes present on the active X chromosome. The current clinical test for the detection of skewed XCI relies on the methylation status of the methylation-sensitive restriction enzyme (Hpall) binding site present in proximity of short tandem polymorphic repeats on the androgen receptor (AR) gene. This approach using one locus results in uninformative or inconclusive data for 10-20% of tests. Further, recent studies have shown inconsistency between methylation of the AR locus and the state of inactivation of the X chromosome. Herein, we develop a method for estimating X inactivation status, using exome and transcriptome sequencing data derived from blood in 227 female samples. We built a reference model for evaluation of XCI in 135 females from the GTEx consortium. We tested and validated the model on 11 female individuals with different types of undiagnosed rare genetic disorders who were clinically tested for X-skew using the AR gene assay and compared results to our outlier-based analysis technique.

resultsIn comparison to the AR clinical test for identification of X inactivation, our method was concordant with the AR method in 9 samples, discordant in 1, and provided a measure of X inactivation in 1 sample with uninformative clinical results. We applied this method on an additional 81 females presenting to the clinic with phenotypes consistent with different hereditary disorders without a known genetic diagnosis.

conclusionsThis study presents the use of transcriptome and exome sequencing data to provide an accurate and complete estimation of X-inactivation and skew status in a cohort of female patients with different types of suspected rare genetic disease.

Indexed as

ExomeX Chromosome InactivationAdultChromosomes, Human, XExome SequencingFemaleHumansTranscriptomeEscapeExome sequencingExpressionNon-random skewRare genetic diseaseSkewed X chromosome inactivationTranscriptome

Identifiers

PMID38627676
PMCPMC11020449
OpenAlexW4394836833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.